Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 2/20 | 0.37 |
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.37 |
| ▸ | EGFR | P00533 | 2/20 | 0.35 |
| ▸ | FPR2 | P25090 | 3/20 | 0.33 |
| ▸ | LMNA | P02545 | 3/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | CSF1R | P07333 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 2/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.31 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.31 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23692939 | 1.00 | LPL (0.37) | LPLLIPGEGFRFPR2LMNA | |
| SCHEMBL30385846 | 0.88 | LPL (0.40) | LPLLIPGEGFRCSF1RTUBB1 | |
| SCHEMBL20508307 | 0.88 | LPL (0.40) | LPLLIPGEGFRCSF1RTUBB1 | |
| SCHEMBL21823670 | 0.87 | FPR2 (0.38) | LPLLIPGEGFRFPR2SMN1; SMN2 | |
| SCHEMBL21918856 | 0.87 | FPR2 (0.37) | LPLLIPGEGFRFPR2SMN1; SMN2 | |
| SCHEMBL25241856 | 0.85 | LPL (0.38) | LPLLIPGEGFR | |
| SCHEMBL21918831 | 0.84 | FPR2 (0.41) | LPLLIPGEGFRFPR2LMNA | |
| SCHEMBL15507443 | 0.84 | LPL (0.37) | LPLLIPGEGFR | |
| SCHEMBL23538053 | 0.83 | EGFR (0.39) | LPLLIPGEGFRCSF1R | |
| SCHEMBL25209269 | 0.83 | LPL (0.36) | LPLLIPGEGFRCSF1RKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220396565-A1 | NOVEL HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2022-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220396565-A1 | NOVEL HETEROCYCLIC COMPOUNDS | MRPL21, F12, MRPS34 | LPL 3989/4885LIPG 4596/4885EGFR 2971/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.